



**For Immediate Release**

**10 December 2008**

## **SENXIS TO COLLABORATE WITH ALZHYNE ON ALZHEIMER'S DIAGNOSTICS**

Cambridge, UK, and Perth, Australia, 10 December 2008 - Senexis Limited and Alzhyne Pty Limited, two private drug development companies, announced today that they have agreed to collaborate on the discovery of novel Alzheimer's diagnostics. The collaboration will exploit the two company's combined resources and intellectual property to accelerate the discovery of a new diagnostic test for the potential early detection of Alzheimer's disease.

Mark Treherne, Senexis' Chief Executive, commented: "We are pleased to be collaborating with Alzhyne. In spite of the attention Alzheimer's disease receives, there is a significant medical need for the early detection of the condition. We now look forward to being able to accelerate the development of a novel Alzheimer's diagnostic test".

Greg Thomas, Alzhyne's Chief Executive Officer, commented: "We believe our combined expertise should give us a competitive advantage in taking these innovative tests forward. We are pleased to be working with Senexis".

The number of people with Alzheimer's disease is expected to double over the next two decades. Currently, five million people in the US alone are affected by the disease.

The pathological processes of Alzheimer's disease begin years before clinical symptoms are observed. Despite Alzheimer's disease being the most common form of dementia, there is no available diagnostic test on the market to diagnose the disease in its early stages. Early diagnosis would provide the best chance for drug and other interventions to treat or slow the progression of the disease before significant brain damage and memory loss occurs.

The aim of the Senexis - Alzhyne collaboration is to develop a reliable, low cost diagnostic test kit for the routine detection of disease biomarkers in the blood. The worldwide market for such a test is estimated to be US\$1billion. The development of an effective and improved method to diagnose Alzheimer's disease has the potential to minimise the enormous global impact



that Alzheimer's disease has on patient health, quality of life and healthcare costs.

## **CONTACTS**

### **Senexis**

Dr. Mark Treherne, Chief Executive  
+44 (0)7711 190 718

### **Alzhyme**

Dr. Greg Thomas, Chief Executive Officer  
+61 (0)415 411 229

### **About Senexis**

Senexis is a growing drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's disease and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Further information on Senexis can be found at [www.senexis.com](http://www.senexis.com).

### **About Alzhyme**

Alzhyme is a privately funded biopharmaceutical company based in Perth, Western Australia committed to the discovery and development of new treatments and diagnostics for the prevention and cure of Alzheimer's disease. The technology arose from research conducted by Professor Ralph Martins and his research teams at The Sir James McCusker Foundation for Alzheimer's Disease Research at Hollywood Private Hospital and The University of Western Australia. Alzhyme was established through an initial capital investment by its founding shareholder and Chairman, Mr. Harold Clough. For further information please visit [www.alzhyme.com](http://www.alzhyme.com).